DRILLAPP JavaScript backdoor targets Ukraine in Feb 2026, abusing Edge debugging features to spy via camera, microphone, and ...

The judge said he didn't follow the correct procedure for what is effectively a move to deny patients care.

The campaign, observed in February 2026, has been assessed to share overlaps with a prior campaign mounted by Laundry Bear, a ...

VectorCertain Analyzed 3,434 OpenClaw Pull Requests Using Multi-Model Consensus, Identified Systemic Governance Failures, and ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...